Federal Register / Vol. 82, No. 182 / Thursday, September 21, 2017 / Notices 44191 

Staff (see ADDRESSES). A link to the 

transcript will also be available on the 

internet at https://www.fda.gov/

AnimalVeterinary/SafetyHealth/ 

AntimicrobialResistance/ 

NationalAntimicrobial

ResistanceMonitoringSystem/ 

ucm059172.htm. 

Dated: September 15, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–20108 Filed 9–20–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Notice of Single-Award Deviation From 

Competition Requirements for the 

Severe Combined Immunodeficiency 

(SCID) Newborn Screening Program at 

the Jeffrey Modell Foundation 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice of award. 

SUMMARY: HRSA announces the award 

of an extension in the amount of 

$2,000,000 for the Severe Combined 

Immunodeficiency (SCID) Newborn 

Screening program at the Jeffrey Modell 

Foundation (JMF). The extension will 

allow JMF, the cooperative agreement 

recipient, during the budget period of 

May 1, 2017 to April 30, 2018, to 

provide technical assistance and 

support to states for the implementation 

of population based newborn screening 

for SCID. 

FOR FURTHER INFORMATION CONTACT: Jill 

F. Shuger, ScM, Division of Services for 

Children with Special Health Needs, 

MCHB, HRSA, 5600 Fishers Lane, 

Rockville, Maryland 20857, Phone: 

(301) 443–3247, Email: JShuger@

hrsa.gov. 

SUPPLEMENTARY INFORMATION: 

Intended Recipient of the Award: 

Jeffrey Modell Foundation. 

Amount of Non-Competitive Awards: 

$2,000,000. 

Budget Period of Supplemental 

Funding: May 1, 2017 to April 30, 2018. 

CFDA Number: 93.110. 

Authority: Public Health Service Act, 

§ 1109, as amended by the Newborn 

Screening Saves Lives Reauthorization 

Act of 2014 (Public Law 110–204) (42 

U.S.C. 300b–8). 

Justification: The Maternal and Child 

Health Bureau (MCHB) is proposing that 

JMF continue activities under the 

current cooperative agreement to ensure 

the implementation of newborn 

screening for SCID in all 50 states, 

particularly in the states that have yet to 

implement SCID screening (i.e., 

Alabama, Arizona, Indiana, Kansas, 

Louisiana, Nevada and North Carolina). 

Using its resources and centers, JMF 

will provide technical assistance in 

areas of funding, state government 

education, and linkage to expert care 

and patient access to a national network 

of specialized treatment centers. 

Further, JMF will continue to support 

states with implementation of SCID 

screening and follow up as well as the 

immediate treatment of infants 

identified with SCID. JMF will use the 

data collected from the states to educate 

clinical immunologists, neonatologists 

and other providers on effective 

screening for SCID. Additionally, JMF 

will continue to support education and 

awareness of newborn screening for 

SCID to families and health care 

providers and provide education to 

primary care providers and medically 

underserved populations. 

Grantee/organization name Grant No. State 

Fiscal year 

2017 

authorized 

funding level 

Fiscal year 

2017 

estimated 

supplemental 

funding 

Jeffrey Modell Foundation ............................................................................... UG5MC28325 UT $2,000,000 $2,000,000 

Dated: September 7, 2017. 

George Sigounas, 

Administrator. 

[FR Doc. 2017–20116 Filed 9–20–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel; T32 

Institutional Training Grant Review. 

Date: October 6, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Dental and 

Craniofacial Research, Democracy One, 6701 

Democracy Blvd., Suite 602, Bethesda, MD 

20892. 

Contact Person: Kan Ma, Ph.D., Scientific 

Review Officer, Scientific Review Branch, 

National Institute of Arthritis, 

Musculoskeletal and Skin Diseases, NIH, 

6701 Democracy Boulevard, Suite 814, 

Bethesda, MD 20892, 301–451–4838, mak2@

mail.nih.gov. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel; Division of 

Musculoskeletal Diseases RISK R61/R33 Peer 

Review. 

Date: October 11, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Rd, 

Bethesda, MD 20852. 

Contact Person: Xincheng Zheng, MD, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, National Institute of 

Arthritis, Musculoskeletal and Skin Diseases, 

NIH, 6701 Democracy Boulevard, Suite 820, 

Bethesda, MD 20892, 301–451–4838, 

xincheng.zheng@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: September 15, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20095 Filed 9–20–17; 8:45 am] 

BILLING CODE 4140–01–P 


asabaliauskas on DSKBBXCHB2PROD with NOTICES